Gilead Sciences, Inc. (GILD) Stock Price, News, Analysis

Technical Score (1D)

BUY

News Sentiment

BULLISH

Gilead Sciences' HIV prevention drug, lenacapavir, is seeing expanded access with PEPFAR and The Global Fund increasing their investment to reach an additional 1 million people in high-incidence countries by 2028, bringing the total commitment to cover up to 3 million individuals. This significant expansion, driven by growing confidence in lenacapavir's potential, is now being supported by the arrival of the first shipment of 37,920 doses in South Africa, which will undergo quality checks before distribution. The increased investment and initial shipments signal progress in Gilead's global health initiatives and highlight the drug's role in public health strategies. Separately, Gilead Sciences was identified as a company with potential positive earnings momentum, based on strong financial performance and upward revisions in earnings estimates. This comes as the company's upcoming earnings report is expected to project year-over-year growth in both EPS and revenue. Despite these positive developments, GILD shares have seen a recent decline over the past month and, while experiencing a modest gain today, lagged broader market indices, suggesting specific company factors are influencing its trajectory. Investors will be watching for the upcoming earnings report and continued progress on lenacapavir's global rollout.

Market Data

GILD Stock Snapshot

Gilead Sciences, Inc. · Healthcare · gilead.com

Gilead Sciences is a biopharmaceutical company focused on discovering, developing, and marketing medicines to address significant unmet medical needs globally. The company's core business centers on treatments for viral diseases, including HIV/AIDS and hepatitis, with a portfolio of established therapies such as Biktarvy, Genvoya, and Epclusa. Beyond virology, Gilead offers oncology products like Yescarta and Trodelvy, as well as treatments for pulmonary arterial hypertension and invasive fungal infections. Gilead leverages strategic collaborations with other pharmaceutical and biotechnology companies, including Arcus Biosciences and Merck, to expand its research and development capabilities and pipeline of potential future therapies. Founded in 1987, the company is headquartered in Foster City, California.

GILD is currently trading at $139.24, giving Gilead Sciences, Inc. a market cap of 173.91B and a P/E ratio of 20.4. Today's range spans $139.01–$139.39, with shares opening at $139.02 and moving down $0.58 (0.4%) from the prior close. DailyIQ's technical score sits at 59/100 (HOLD) with a news sentiment reading of 67/100.

Over the past year GILD has traded between $93.37 and $157.29 - the current price is +49.1% off the 52-week low and -11.5% from the high. 39 analysts cover the stock with a Buy consensus and a mean 12-month target of $151.84 (range $125.00–$171.00), implying upside of +9.0%.

GILD trades at $139.24 (in the upper portion of its 52-week range within $93.37–$157.29) - and the HOLD signal (59/100) reflects a market that's fairly priced relative to near-term expectations rather than one that's mispriced in either direction. (P/E: 20.4) At 173.91B in Healthcare market cap, bullish sentiment (67/100) confirms the lack of near-term narrative catalyst. The thesis is intact; the timing is patient.

GILD|EarningsGilead Sciences, Inc.

Earnings Summary

Gilead Sciences is a biopharmaceutical company focused on developing and marketing medicines for significant unmet medical needs, with core strengths in treatments for viral diseases like HIV/AIDS and hepatitis, as well as oncology and pulmonary arterial hypertension. The company leverages strategic collaborations to expand its research and development pipeline. Gilead's recent quarterly performance indicates a generally positive trend in both earnings per share (EPS) and revenue against analyst expectations. In Q4 2025, the company reported EPS of $1.86, missing the estimate of $1.98, but revenue reached $7.93 billion, exceeding the estimate of $6.94 billion. Prior quarters showed consistent beats, with Q3 2025 EPS at $2.47 (vs. $2.14 est.) and revenue at $7.77 billion (vs. null est.), and Q2 2025 EPS at $2.01 (vs. $1.96 est.). The company has a history of exceeding analyst expectations, with recent quarters showing strong EPS growth, such as Q3 2025's significant beat. Recent news indicates a strategic pivot towards oncology, highlighted by the $5 billion acquisition of Tubulis GmbH for its antibody-drug conjugate technology, alongside other strategic collaborations and licensing agreements with companies like Arcellx and Kymera Therapeutics. These moves aim to diversify Gilead's revenue streams beyond its established HIV franchise. Investors should watch for the successful integration of new oncology assets and the progression of pipeline candidates, particularly those acquired or licensed recently, as these will be key drivers for future revenue growth and diversification. The company's ability to translate these strategic investments into clinical and commercial success will be critical.

Earnings | EPS

EstBeatMiss

Qtr	Est	Actual	+/−
Q1'26	$1.91	-	-
Q4'25	$1.98	$1.86	-6.2%
Q3'25	$2.14	$2.47	+15.7%
Q2'25	$1.96	$2.01	+2.7%
Q1'25	$1.78	$1.81	+1.9%
Q4'24	$1.70	$1.90	+11.7%

Revenue

EstBeatMiss

Qtr	Est	Actual	+/−
Q1'26	$6.9B	-	-
Q4'25	$6.9B	$7.9B	+14.1%
Q3'25	-	$7.8B	-
Q2'25	-	$7.1B	-
Q1'25	-	$6.7B	-
Q4'24	-	$7.6B	-

Technical Score (1D)

BUY

News Sentiment

BULLISH

Market Data

GILD Stock Snapshot

Gilead Sciences, Inc. · Healthcare · gilead.com

News Sentiment Analysis

Sentiment gathered from recent headlines

67/100

Strong NegativeNeutralStrong Positive

MODERATELY BULLISH

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles

What did this article say?

South Africa has received its initial consignment of lenacapavir, a twice-yearly anti-HIV injection developed by Gilead Sciences. The arrival of 37,920 doses marks a significant step in the country's efforts to combat HIV. The medication will now undergo quality checks before distribution.

What did this article say?

Gilead Sciences (GILD) experienced a stock price increase today, though its performance trailed the broader market. This divergence suggests underlying factors influencing GILD's specific trajectory independent of general market sentiment. Investors should monitor the company's individual news flow and pipeline developments for further insights into its performance drivers.

What did this article say?

Gilead Sciences (GILD) will see expanded access to its twice-yearly injectable HIV prevention medicine, lenacapavir. PEPFAR and The Global Fund are increasing their investment to reach an additional 1 million people in high-incidence, resource-limited countries through 2028. This brings the total commitment to cover up to 3 million individuals. The expanded access is a key component of Gilead's global health initiatives.

What did this article say?

Gilead Sciences (GILD) announced that PEPFAR and The Global Fund are making an additional investment in its lenacapavir drug for HIV prevention. This initiative aims to further expand access to the medication. Initial shipments of lenacapavir are underway, signaling progress in its distribution.

What did this article say?

The U.S. and the Global Fund are significantly increasing their commitment to expand access to Gilead's HIV prevention drug. This initiative aims to reach 3 million individuals by 2028, signaling a substantial global health effort. The expanded program underscores the importance of GILD's preventative treatments in public health strategies.

What did this article say?

Gilead Sciences (GILD) is mentioned as one of two medical companies identified for potential positive earnings momentum. The article references the Zacks Earnings ESP tool as a method for identifying stocks likely to exceed quarterly earnings expectations. Investors are directed to a report for further stock recommendations.

What did this article say?

An investment of $100 in Gilead Sciences (GILD) stock 20 years ago would now be worth approximately $861.20, reflecting an annualized return of 11.42%. This performance has outpaced the broader market by 2.74% over the same period. The analysis highlights the power of compounded returns over long investment horizons.

What did this article say?

Gilead Sciences (GILD) is extending the reach of its lenacapavir for HIV prevention in high-incidence countries through 2028. This expansion, supported by the U.S. State Department, PEPFAR, and The Global Fund, aims to provide access to an additional million people over the next three years. The collaboration underscores a commitment to broader public health solutions.

What did this article say?

AIDS Healthcare Foundation (AHF) is organizing protests at Gilead Sciences' headquarters, criticizing the company's pricing for HIV medications. The high cost of drugs like Biktarvy, with an annual sticker price near $61,000, is cited as a strain on state AIDS Drug Assistance Programs (ADAPs). This pricing strategy is highlighted as a factor in Florida's decision to restrict ADAP access, intensifying scrutiny on Gilead's pricing policies.

What did this article say?

Old North State Wealth Management LLC has reduced its holdings in Gilead Sciences by 7.7%, selling 4,182 shares in the fourth quarter. This adjustment leaves the fund with 50,385 shares, representing 2.9% of its portfolio and marking it as its sixth-largest position. The transaction occurred as other institutional investors, such as Invesco Ltd. and Legal & General Group Plc, have recently increased their stakes in the biopharmaceutical company.

GILD|EarningsGilead Sciences, Inc.

Earnings Summary

Earnings | EPS

EstBeatMiss

Qtr	Est	Actual	+/−
Q1'26	$1.91	-	-
Q4'25	$1.98	$1.86	-6.2%
Q3'25	$2.14	$2.47	+15.7%
Q2'25	$1.96	$2.01	+2.7%
Q1'25	$1.78	$1.81	+1.9%
Q4'24	$1.70	$1.90	+11.7%

Revenue

EstBeatMiss

Qtr	Est	Actual	+/−
Q1'26	$6.9B	-	-
Q4'25	$6.9B	$7.9B	+14.1%
Q3'25	-	$7.8B	-
Q2'25	-	$7.1B	-
Q1'25	-	$6.7B	-
Q4'24	-	$7.6B	-

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles

What did this article say?

GILD·Gilead Sciences, Inc.

GILD Stock Snapshot

Earnings | EPS

Revenue

GILD·Gilead Sciences, Inc.

GILD Stock Snapshot

News Sentiment Analysis

Recent News Coverage

Earnings | EPS

Revenue

News Sentiment Analysis

Recent News Coverage

GILD·Gilead Sciences, Inc.

GILD Stock Snapshot

Earnings | EPS

Revenue

GILD·Gilead Sciences, Inc.

GILD Stock Snapshot

News Sentiment Analysis

Recent News Coverage

Earnings | EPS

Revenue

Discover More

News Sentiment Analysis

Recent News Coverage

Discover More